Device Trial Radar · NCT01851252
MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy
Last checked: Nov 20, 2026Latest source record: Dec 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Oct 2013
Primary completion
Aug 2017
Study completion Aug 2017
Sponsor
- Lead sponsor
- Meridian Bioscience, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effect on the (carbon 13 labelled(13C)-Methacetin Breath Test (MBT) of i.v. propranolol, a non-selective beta blocker (NSBB) following initial administration and after chronic use of each of these agents. The correlation of the MBT with Hepatic Venous Pressure Gradient (HVPG) measurement before and after treatment will be assessed. Additionally, the MBT measurements following 60 days of therapy will be compared to the first MBT measurement and to the second MBT measurement, post HVPG. Each patient's subsequent MBT measurement will be compared to his previous MBT results in order to determine his/her response to therapy.
Conditions
- Chronic Liver Disease
- Cirrhosis
- Esophageal Varices
- Portal Hypertension
- Bleeding
Interventions
Methacetin (with Breath testing device)Device
The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Correlation between HVPG and MBT and their changes following the i.v. administration of PropranololTime frame: 7 days
- The changes between MBT at baseline level and after chronic treatment in PropranololTime frame: 7 days
- MBT correlation to clinical events after 2 month of treatmentTime frame: 67 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Carmel Medical Center
Haifa, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.